Literature DB >> 23423416

Insomnia.

Daniel J Buysse1.   

Abstract

IMPORTANCE: Insomnia is one of the most prevalent health concerns in the population and in clinical practice. Clinicians may be reluctant to address insomnia because of its many potential causes, unfamiliarity with behavioral treatments, and concerns about pharmacologic treatments.
OBJECTIVE: To review the assessment, diagnosis, and treatment of insomnia in adults. EVIDENCE REVIEW: Systematic review to identify and summarize previously published quantitative reviews (meta-analyses) of behavioral and pharmacologic treatments for insomnia.
FINDINGS: Insomnia is a common clinical condition characterized by difficulty initiating or maintaining sleep, accompanied by symptoms such as irritability or fatigue during wakefulness. The prevalence of insomnia disorder is approximately 10% to 20%, with approximately 50% having a chronic course. Insomnia is a risk factor for impaired function, development of other medical and mental disorders, and increased health care costs. The etiology and pathophysiology of insomnia involve genetic, environmental, behavioral, and physiological factors culminating in hyperarousal. The diagnosis of insomnia is established by a thorough history of sleep behaviors, medical and psychiatric problems, and medications, supplemented by a prospective record of sleep patterns (sleep diary). Quantitative literature reviews (meta-analyses) support the efficacy of behavioral, cognitive, and pharmacologic interventions for insomnia. Brief behavioral interventions and Internet-based cognitive-behavioral therapy both show promise for use in primary care settings. Among pharmacologic interventions, the most evidence exists for benzodiazepine receptor agonist drugs, although persistent concerns focus on their safety relative to modest efficacy. Behavioral treatments should be used whenever possible, and medications should be limited to the lowest necessary dose and shortest necessary duration. CONCLUSIONS AND RELEVANCE: Clinicians should recognize insomnia because of its effects on function and health. A thorough clinical history is often sufficient to identify factors that contribute to insomnia. Behavioral treatments should be used when possible. Hypnotic medications are also efficacious but must be carefully monitored for adverse effects.

Entities:  

Mesh:

Year:  2013        PMID: 23423416      PMCID: PMC3632369          DOI: 10.1001/jama.2013.193

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  61 in total

Review 1.  Comparative meta-analysis of behavioral interventions for insomnia and their efficacy in middle-aged adults and in older adults 55+ years of age.

Authors:  Michael R Irwin; Jason C Cole; Perry M Nicassio
Journal:  Health Psychol       Date:  2006-01       Impact factor: 4.267

2.  The consensus sleep diary: standardizing prospective sleep self-monitoring.

Authors:  Colleen E Carney; Daniel J Buysse; Sonia Ancoli-Israel; Jack D Edinger; Andrew D Krystal; Kenneth L Lichstein; Charles M Morin
Journal:  Sleep       Date:  2012-02-01       Impact factor: 5.849

3.  Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia.

Authors:  Andrew D Krystal; Alan Lankford; H Heith Durrence; Elizabeth Ludington; Philip Jochelson; Roberta Rogowski; Thomas Roth
Journal:  Sleep       Date:  2011-10-01       Impact factor: 5.849

4.  Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders, Second Edition criteria: results from the America Insomnia Survey.

Authors:  Thomas Roth; Catherine Coulouvrat; Goeran Hajak; Matthew D Lakoma; Nancy A Sampson; Victoria Shahly; Alicia C Shillington; Judith J Stephenson; James K Walsh; Ronald C Kessler
Journal:  Biol Psychiatry       Date:  2010-12-31       Impact factor: 13.382

5.  Insomnia and the risk of acute myocardial infarction: a population study.

Authors:  Lars E Laugsand; Lars J Vatten; Carl Platou; Imre Janszky
Journal:  Circulation       Date:  2011-10-24       Impact factor: 29.690

Review 6.  Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies.

Authors:  Chiara Baglioni; Gemma Battagliese; Bernd Feige; Kai Spiegelhalder; Christoph Nissen; Ulrich Voderholzer; Caterina Lombardo; Dieter Riemann
Journal:  J Affect Disord       Date:  2011-02-05       Impact factor: 4.839

Review 7.  Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation.

Authors:  Y Dündar; A Boland; J Strobl; S Dodd; A Haycox; A Bagust; J Bogg; R Dickson; T Walley
Journal:  Health Technol Assess       Date:  2004-06       Impact factor: 4.014

Review 8.  The hyperarousal model of insomnia: a review of the concept and its evidence.

Authors:  Dieter Riemann; Kai Spiegelhalder; Bernd Feige; Ulrich Voderholzer; Mathias Berger; Michael Perlis; Christoph Nissen
Journal:  Sleep Med Rev       Date:  2009-05-28       Impact factor: 11.609

Review 9.  A systematic review of valerian as a sleep aid: safe but not effective.

Authors:  Diana M Taibi; Carol A Landis; Heidi Petry; Michael V Vitiello
Journal:  Sleep Med Rev       Date:  2007-06       Impact factor: 11.609

Review 10.  A cognitive model of insomnia.

Authors:  A G Harvey
Journal:  Behav Res Ther       Date:  2002-08
View more
  205 in total

1.  Varying Hypopnea Definitions Affect Obstructive Sleep Apnea Severity Classification and Association With Cardiovascular Disease.

Authors:  Christine H J Won; Li Qin; Bernardo Selim; Henry K Yaggi
Journal:  J Clin Sleep Med       Date:  2018-12-15       Impact factor: 4.062

Review 2.  Perimenopause: From Research to Practice.

Authors:  Nanette Santoro
Journal:  J Womens Health (Larchmt)       Date:  2015-12-10       Impact factor: 2.681

Review 3.  Menopausal Symptoms and Their Management.

Authors:  Nanette Santoro; C Neill Epperson; Sarah B Mathews
Journal:  Endocrinol Metab Clin North Am       Date:  2015-09       Impact factor: 4.741

4.  Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension.

Authors:  Neely Ivgy-May; Goeran Hajak; Gonnie van Osta; Sabine Braat; Qing Chang; Thomas Roth
Journal:  J Clin Sleep Med       Date:  2020-09-15       Impact factor: 4.062

5.  Sleep Quality Among Low-Income Young Women in Southeast Texas Predicts Changes in Perceived Stress Through Hurricane Ike.

Authors:  Zhao Helen Wu; Richard G Stevens; Howard Tennen; Carol S North; James J Grady; Charles Holzer
Journal:  Sleep       Date:  2015-07-01       Impact factor: 5.849

6.  Objective measures are useful in subtyping chronic insomnia.

Authors:  Alexandros N Vgontzas; Julio Fernandez-Mendoza
Journal:  Sleep       Date:  2013-08-01       Impact factor: 5.849

Review 7.  Insomnia in the Elderly: A Review.

Authors:  Dhaval Patel; Joel Steinberg; Pragnesh Patel
Journal:  J Clin Sleep Med       Date:  2018-06-15       Impact factor: 4.062

8.  Association between insomnia and atrial fibrillation in a Chinese population: A cross-sectional study.

Authors:  Xu Han; Yiheng Yang; Yue Chen; Lianjun Gao; Xiaomeng Yin; Huihua Li; Jing Qiu; Youxin Wang; Yong Zhou; Yunlong Xia
Journal:  Clin Cardiol       Date:  2017-05-31       Impact factor: 2.882

9.  Mild cognitive impairment: associations with sleep disturbance, apolipoprotein e4, and sleep medications.

Authors:  Shanna L Burke; Tianyan Hu; Christine E Spadola; Tan Li; Mitra Naseh; Aaron Burgess; Tamara Cadet
Journal:  Sleep Med       Date:  2018-09-20       Impact factor: 3.492

10.  Association of Sexual Harassment and Sexual Assault With Midlife Women's Mental and Physical Health.

Authors:  Rebecca C Thurston; Yuefang Chang; Karen A Matthews; Roland von Känel; Karestan Koenen
Journal:  JAMA Intern Med       Date:  2019-01-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.